1. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer. Lu W, Liu S, Li B, Xie Y, Izban MG, Ballard BR, Sathyanarayana SA, Adunyah SE, Matusik RJ, Chen Z (2017) Oncogene 36(10): 1364-1373
    › Primary publication · 27869166 (PubMed)
  2. NF-κB and androgen receptor variant expression correlate with human BPH progression. Austin DC, Strand DW, Love HL, Franco OE, Jang A, Grabowska MM, Miller NL, Hameed O, Clark PE, Fowke JH, Matusik RJ, Jin RJ, Hayward SW (2016) Prostate 76(5): 491-511
    › Primary publication · 26709083 (PubMed) · PMC4763342 (PubMed Central)
  3. NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. Austin DC, Strand DW, Love HL, Franco OE, Grabowska MM, Miller NL, Hameed O, Clark PE, Matusik RJ, Jin RJ, Hayward SW (2016) Prostate 76(11): 1004-18
    › Primary publication · 27197599 (PubMed) · PMC4912960 (PubMed Central)
  4. Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia. Grabowska MM, Kelly SM, Reese AL, Cates JM, Case TC, Zhang J, DeGraff DJ, Strand DW, Miller NL, Clark PE, Hayward SW, Gronostajski RM, Anderson PD, Matusik RJ (2016) Endocrinology 157(3): 1094-109
    › Primary publication · 26677878 (PubMed) · PMC4769366 (PubMed Central)
  5. Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression. Qiao J, Grabowska MM, Forestier-Roman IS, Mirosevich J, Case TC, Chung DH, Cates JM, Matusik RJ, Manning HC, Jin R (2016) Oncotarget 7(38): 61955-61969
    › Primary publication · 27542219 (PubMed) · PMC5308703 (PubMed Central)
  6. SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination. Lu W, Liu S, Li B, Xie Y, Adhiambo C, Yang Q, Ballard BR, Nakayama KI, Matusik RJ, Chen Z (2015) Oncotarget 6(2): 771-88
    › Primary publication · 25596733 (PubMed) · PMC4359254 (PubMed Central)
  7. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. Reddy OL, Cates JM, Gellert LL, Crist HS, Yang Z, Yamashita H, Taylor JA, Smith JA, Chang SS, Cookson MS, You C, Barocas DA, Grabowska MM, Ye F, Wu XR, Yi Y, Matusik RJ, Kaestner KH, Clark PE, DeGraff DJ (2015) Am J Pathol 185(5): 1385-95
    › Primary publication · 25907831 (PubMed) · PMC4419202 (PubMed Central)
  8. Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Jin R, Yamashita H, Yu X, Wang J, Franco OE, Wang Y, Hayward SW, Matusik RJ (2015) Oncogene 34(28): 3700-10
    › Primary publication · 25220414 (PubMed) · PMC4362792 (PubMed Central)
  9. SOX2 expression in the developing, adult, as well as, diseased prostate. Yu X, Cates JM, Morrissey C, You C, Grabowska MM, Zhang J, DeGraff DJ, Strand DW, Franco OE, Lin-Tsai O, Hayward SW, Matusik RJ (2014) Prostate Cancer Prostatic Dis 17(4): 301-9
    › Primary publication · 25091041 (PubMed) · PMC4227931 (PubMed Central)
  10. Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis. Xie Y, Liu S, Lu W, Yang Q, Williams KD, Binhazim AA, Carver BS, Matusik RJ, Chen Z (2014) Mol Oncol 8(7): 1355-64
    › Primary publication · 24910389 (PubMed) · PMC4198473 (PubMed Central)